Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.Calcified tissue international · 2023
   Article
2. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.Journal of bone and mineral metabolism · 2021
   Article
3. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.Journal of bone and mineral metabolism · 2021
   Article
4. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.Journal of bone and mineral metabolism · 2019
   Article
5. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.Journal of bone and mineral metabolism · 2018
   Observational
6. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
   Article
7. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.Journal of bone and mineral metabolism · 2017
   Article
8. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.Journal of bone and mineral metabolism · 2017
   Observational
9. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
   Observational

Corrections and comments

• Comment on
  Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.2014
• Comment on
  Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in rheumatoid arthritis patients.2015

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as